Daniel Bouthillier


Daniel Bouthillier has over 25 years of experience in research administration. He is presently President and CEO of Kanyr Pharma, a biotechnology start-up company dedicated to develop a dendritic cell-based technology to treat cancer. For the last five years, as General Manager he was managing the Quebec Network for Personalized Health Care, an organization dedicated to promote and integrate personalized health care in our health system. Previously Mr. Bouthillier occupied various positions at Merck&Co where he was Executive Director of Research Administration and Planning for various research sites in North America. He was also Executive Director for Merck Global Facilities Management with responsibilities for Canada, US and foreign sites. In previous positions, Mr. Bouthillier was Senior Scientist and Administrator at the Clinical Research Institute of Montreal and also Head of Biochemistry at lâ??Hôtel-Dieu de Sorel and at Fleury Hospital in Montreal. He sits on many evaluation committees and boards such as Centre québécois dâ??innovation en biotechnologie (CQIB), BiogeniQ, Kaneq Bioscience and Kanyr Pharma. Mr. Bouthillier received his Ph.D. in Clinical Sciences from the Université de Montréal and holds a certification in Clinical Biochemistry. He also completed an MBA at lâ??Ã?cole des Hautes Ã?tudes Commerciales in Montreal.

Published Works

Contact details


Areas of Practice

Life Sciences


Ph.D., MBA and Certification in Clinical Biochemistry


Member of Ordre des chimistes du Québec